Amgen, Kleiner Perkins Spin-Out Atara Sails Into The Spotlight
This article was originally published in The Pink Sheet Daily
Executive Summary
Launched in fall 2012 via a partnership between Amgen and Kleiner Perkins Caufield & Byers, the Bay Area biotech has three subsidiary companies housing six biologic assets that used to belong to Amgen. With two financing rounds this year totaling $58.5 million, three candidates are slated to enter the clinic by 2015.